Scholars Central

Conference abstractPublished 2 Oct 2017

Target Based vs. Phenotypic Screening Approaches in Drug Discovery

Authors: Tove Tuntland

Genomics Institute of Novartis Research Foundation (GNF), USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Target-based drug discovery can effectively develop novel treatments for a validated target, but the process of target validation is complex and associated with high degree of uncertainty[1]. As an alternative to the target based approach, phenotypic screening is making a comeback in drug discovery. Such assays characterize phenotypic events related to disease modification and do not require prior understanding of the mechanism of action[2]. At GNF/Novartis, scientists have used both target based and phenotypic screening approaches to successfully identify novel drugs. Target based methods lead to the discovery of ceritinib (Zykadia™, formerly LDK378), a highly potent and selective anaplastic lymphoma kinase (ALK) inhibitor which was recently approved by the FDA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who were previously treated with crizotinib. Phenotypic screening led to the discovery of cipargamin (KAE609), the first new antimalarial drug candidate with a completely novel mechanism of action to reach phase 2 clinical development in over 20 years. When tested clinically in adults with uncomplicated P. vivax or P. falciparum malaria, cipargamin was shown to clear parasitemia after 3 days of repeated dosing. Also identified by phenotypic screening, the novel antimalarial drug KAF156 demonstrated activity against both liver and blood stage malaria, including artemisinin-resistant parasites. The approaches used to discover and develop the novel drugs ceritinib, cipargamin and KAF156 will be discussed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Tove Tuntland”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels